143 related articles for article (PubMed ID: 37768837)
21. Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review.
Halderman AA; Ryan MW; Clark C; Sindwani R; Reh DD; Poetker DM; Invernizzi R; Marple BF
Int Forum Allergy Rhinol; 2018 Jun; 8(6):713-728. PubMed ID: 29393992
[TBL] [Abstract][Full Text] [Related]
22. Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding.
Beckman JD; Li Q; Hester ST; Leitner O; Smith KL; Kasthuri RS
Orphanet J Rare Dis; 2020 Jul; 15(1):185. PubMed ID: 32660636
[TBL] [Abstract][Full Text] [Related]
23. The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey.
Zaffar N; Ravichakaravarthy T; Faughnan ME; Shehata N
Ann Hematol; 2015 Jan; 94(1):145-52. PubMed ID: 25064693
[TBL] [Abstract][Full Text] [Related]
24. Tranexamic acid for patients with nasal haemorrhage (epistaxis).
Joseph J; Martinez-Devesa P; Bellorini J; Burton MJ
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD004328. PubMed ID: 30596479
[TBL] [Abstract][Full Text] [Related]
25. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
[TBL] [Abstract][Full Text] [Related]
26. Bleeding management in palliative medicine: subcutaneous tranexamic acid - retrospective chart review.
Howard P; Curtin J
BMJ Support Palliat Care; 2024 Jan; 13(e3):e802-e806. PubMed ID: 35121592
[TBL] [Abstract][Full Text] [Related]
27. Clinical features and treatment of hereditary hemorrhagic telangiectasia.
Li S; Wang SJ; Zhao YQ
Medicine (Baltimore); 2018 Aug; 97(31):e11687. PubMed ID: 30075565
[TBL] [Abstract][Full Text] [Related]
28. Understanding hereditary hemorrhagic telangiectasia: From genetic anomalies to systemic manifestations, quality of life, and epistaxis management-Exploring the otolaryngologist's integral role.
Hayama M; Maeda Y; Obata S; Tsuda T; Takeda K; Nishida T; Inohara H
Auris Nasus Larynx; 2024 Apr; 51(2):305-312. PubMed ID: 38008660
[TBL] [Abstract][Full Text] [Related]
29. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
[TBL] [Abstract][Full Text] [Related]
30. Acute confusion in an elderly woman with Rendu-Osler-Weber disease.
Pollak L; Strauss S; Sanset S; Peer A; Tishler M
Isr Med Assoc J; 2006 Dec; 8(12):886-7. PubMed ID: 17214115
[No Abstract] [Full Text] [Related]
31. Digital Clubbing in Hereditary Hemorrhagic Telangiectasia/Juvenile Polyposis Syndrome.
Mrzljak A; Popić J; Ožanić Bulić S
Acta Dermatovenerol Croat; 2021 Apr; 291(1):56-57. PubMed ID: 34477067
[TBL] [Abstract][Full Text] [Related]
32. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab.
Fleagle JM; Bobba RK; Kardinal CG; Freter CE
Am J Med Sci; 2012 Mar; 343(3):249-51. PubMed ID: 22227516
[TBL] [Abstract][Full Text] [Related]
33. Hereditary haemorrhagic telangiectasia (HHT): negotiating between the Scylla of bleeding and Charybdis of thrombosis.
Ghosh K; Ghosh K
Thromb Haemost; 2008 Jul; 100(1):162-4. PubMed ID: 18612556
[No Abstract] [Full Text] [Related]
34. [Iron deficiency anemia in a patient with hereditary hemorrhagic telangiectasia. Case report].
Mozdon MA; Ponomarev RV; Tsvetaeva NV; Shabrin AV; Ermachenkova EI; Larichev SE; Lukina EA
Ter Arkh; 2023 Sep; 95(7):580-585. PubMed ID: 38159009
[TBL] [Abstract][Full Text] [Related]
35. Bleeding Control in Palliative Care Patients With the Help of Tranexamic Acid.
Geist MJP; Kessler J; Frankenhauser S; Bardenheuer HJ
J Palliat Care; 2017 Apr; 32(2):47-48. PubMed ID: 28920517
[TBL] [Abstract][Full Text] [Related]
36. A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT).
Zarrabeitia R; Albiñana V; Salcedo M; Señaris-Gonzalez B; Fernandez-Forcelledo JL; Botella LM
Curr Vasc Pharmacol; 2010 Jul; 8(4):473-81. PubMed ID: 19485912
[TBL] [Abstract][Full Text] [Related]
37. Systemic Antiangiogenic Therapies for Bleeding in Hereditary Hemorrhagic Telangiectasia: A Practical, Evidence-Based Guide for Clinicians.
Al-Samkari H
Semin Thromb Hemost; 2022 Jul; 48(5):514-528. PubMed ID: 35226946
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial.
Peterson AM; Lee JJ; Kallogjeri D; Schneider JS; Chakinala MM; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1006-1014. PubMed ID: 32940653
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.
Lupu A; Stefanescu C; Treton X; Attar A; Corcos O; Bouhnik Y
J Clin Gastroenterol; 2013 Mar; 47(3):256-7. PubMed ID: 23164683
[TBL] [Abstract][Full Text] [Related]
40. Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life.
Baysal M; Ümit EG; Kırkızlar HO; Özdöver AC; Demir AM
Turk J Haematol; 2019 Feb; 36(1):43-47. PubMed ID: 29880465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
